Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir
Cytomegalovirus (CMV) infections may increase morbidity and mortality in immunocompromised patients. Until recently, standard antiviral drugs against CMV were limited to viral DNA polymerase inhibitors (val)ganciclovir, foscarnet and cidofovir with a risk for cross-resistance. These drugs may also c...
Saved in:
Main Authors: | Jocelyne Piret (Author), Guy Boivin (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients
by: Razonable RR
Published: (2024) -
Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
by: Gandhi RG, et al.
Published: (2022) -
The Use of Letermovir for Ganci clovi r-Res istan t Cytomegalovirus in Kidney Transplant Recipients
by: Nikolina Bašić-Jukić, et al.
Published: (2022) -
Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
by: Kefeng Sun, et al.
Published: (2023) -
Maribavir: Mechanism of action, clinical, and translational science
by: Kefeng Sun, et al.
Published: (2024)